{"nctId":"NCT00855959","briefTitle":"Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients","startDateStruct":{"date":"2009-02"},"conditions":["Asthma"],"count":108,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Pulmicort Turbuhaler"]}],"interventions":[{"name":"Budesonide","otherNames":["Pulmicort"]},{"name":"Pulmicort Turbuhaler","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures.\n* A minimum of 6 months documented history of asthma according to the JGL 2006 definition\n* Asthma patients under prescribed treatment with ICS at least 3 months before Visit 2.\n\nExclusion Criteria:\n\n* Current or previous tobacco smokers with a history of \\>= 10 pack-years\n* Use of Î²-blockers including eye drops\n* Clinically significant respiratory infection affecting the asthma, as judged by the investigator(s) within 4 weeks prior to visit 2\n* Intake of oral, rectal or parenteral GCS within 4 weeks prior to Visit 2","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Morning Peak Expiratory Flow (mPEF)","description":"Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"21.4"}]}]}]},{"type":"SECONDARY","title":"Evening Peak Expiratory Flow (ePEF)","description":"Change in evening peak expiratory flow (ePEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"18.1"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)","description":"Change in Asthma symptom score (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.018","spread":"0.198"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)","description":"Change in Asthma symptom score (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":"0.185"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)","description":"Change in Asthma symptom score (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.039","spread":"0.346"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication (Daytime)","description":"Change in Use of rescue medication (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.017","spread":"0.160"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication (Night-time)","description":"Change in Use of rescue medication (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.044","spread":"0.220"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication (Total)","description":"Change in Use of rescue medication (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.061","spread":"0.317"}]}]}]},{"type":"SECONDARY","title":"Night-time Awakenings Due to Asthma Symptoms","description":"Change in Night-time awakenings due to asthma symptoms from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.004","spread":"0.165"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV 1.0)","description":"Change in Forced Expiratory Volume in 1 second (FEV 1.0) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.079","spread":"0.244"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC)","description":"Change in Forced Vital Capacity (FVC) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.105","spread":"0.283"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"Number of participants with AEs reported during the period on Pulmicort Respules","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Nasopharyngitis"]}}}